Assessment of B-type natriuretic peptide in patients with pneumonia

Basit Öğe Kaydı
dc.authoridGunen, Hakan/0000-0001-6631-4457
dc.authoridHacievliyagil, Suleyman Savas/0000-0002-2572-1870
dc.authorwosidGunen, Hakan/HKV-9202-2023
dc.authorwosidHacievliyagil, Suleyman Savas/ABI-7307-2020
dc.contributor.authorYetkin, O.
dc.contributor.authorHacievliyagil, S. S.
dc.contributor.authorGunen, H.
dc.date.accessioned2024-08-04T20:30:40Z
dc.date.available2024-08-04T20:30:40Z
dc.date.issued2008
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe mammalian heart synthesises and secretes B-type natriuretic peptide (BNP), which has potent diuretic, natriuretic and vascular smooth muscle-relaxing effects as well as complex interactions with the hormonal and nervous systems. Recent studies described that BNP was acute phase reactant. In this study, we aimed to evaluate BNP levels in patients with pneumonia. Twenty-one patients with pneumonia and 21 healthy control subjects were enrolled in this study. Their serum levels of BNP were measured in addition to the standard evaluations. Leucocyte count [19.3 (13.2-25.7) 10(6)/Ml VS. 9.55 (3.7-13.9) 106/Ml, p < 0.0011, erythrocyte sedimentation rate [73 (57-81) mm/h vs. 35 (4-55) mm/h, p < 0.001], C-reactive protein (CRP) [127.72 (27-290) mg/l vs. 13.19 (3-41) mg/l, p < 0.0011 and BNP [53.1 (17-91) pg/ml vs. 16.24 (1-38) pg/ml, p < 0.0011 levels significantly decreased after treatment period. Initial BNP levels were significantly higher than control groups (53.10 +/- 15.07 pg/ml vs. 18.62 +/- 14.05 pg/ml, p < 0.001) and decreased after treatment to the levels comparable with control subjects. BNP levels correlated with CRP levels at admission (r = 0.716, p < 0.001). We have shown that BNP levels show a transient increase in patients with pneumonia and correlate well with CRP.en_US
dc.identifier.doi10.1111/j.1742-1241.2007.01305.x
dc.identifier.endpage491en_US
dc.identifier.issn1368-5031
dc.identifier.issn1742-1241
dc.identifier.issue3en_US
dc.identifier.pmid17916178en_US
dc.identifier.scopus2-s2.0-38849192395en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage488en_US
dc.identifier.urihttps://doi.org/10.1111/j.1742-1241.2007.01305.x
dc.identifier.urihttps://hdl.handle.net/11616/94449
dc.identifier.volume62en_US
dc.identifier.wosWOS:000253675400027en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofInternational Journal of Clinical Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCommunity-Acquired Pneumoniaen_US
dc.subjectRisk Stratificationen_US
dc.subjectHeart-Failureen_US
dc.subjectBrainen_US
dc.subjectHepatocytesen_US
dc.subjectProteinen_US
dc.subjectDiseaseen_US
dc.titleAssessment of B-type natriuretic peptide in patients with pneumoniaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu